Stryker Co. (SYK) Receives Consensus Rating of “Buy” from Brokerages

Share on StockTwits

Stryker Co. (NYSE:SYK) has received an average rating of “Buy” from the twenty-four analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $196.51.

Several equities research analysts have recently weighed in on the company. Canaccord Genuity upped their price target on Stryker from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, January 30th. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research report on Monday, February 4th. Morgan Stanley reduced their price target on shares of Stryker from $212.00 to $197.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 2nd. Deutsche Bank increased their price objective on Stryker from $181.00 to $208.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada increased their price objective on Stryker from $184.00 to $204.00 and gave the company an “outperform” rating in a research note on Monday, March 11th.

In related news, VP Katherine Ann Owen sold 29,247 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $185.62, for a total value of $5,428,828.14. Following the completion of the sale, the vice president now owns 11,131 shares of the company’s stock, valued at $2,066,136.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Yin C. Becker sold 15,240 shares of the firm’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $198.03, for a total value of $3,017,977.20. Following the completion of the sale, the vice president now directly owns 16,577 shares of the company’s stock, valued at approximately $3,282,743.31. The disclosure for this sale can be found here. Insiders sold 130,455 shares of company stock valued at $24,723,292 in the last ninety days. 7.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tokio Marine Asset Management Co. Ltd. raised its holdings in Stryker by 11.5% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 37,702 shares of the medical technology company’s stock worth $7,447,000 after purchasing an additional 3,900 shares in the last quarter. First Merchants Corp raised its holdings in Stryker by 2.6% in the first quarter. First Merchants Corp now owns 57,490 shares of the medical technology company’s stock worth $11,355,000 after purchasing an additional 1,467 shares in the last quarter. Baystate Wealth Management LLC increased its holdings in shares of Stryker by 13.2% during the first quarter. Baystate Wealth Management LLC now owns 1,217 shares of the medical technology company’s stock valued at $225,000 after acquiring an additional 142 shares in the last quarter. Virginia Retirement Systems ET AL increased its holdings in shares of Stryker by 553.0% during the first quarter. Virginia Retirement Systems ET AL now owns 108,400 shares of the medical technology company’s stock valued at $21,411,000 after acquiring an additional 91,800 shares in the last quarter. Finally, Brand Asset Management Group Inc. increased its holdings in shares of Stryker by 3,786.4% during the first quarter. Brand Asset Management Group Inc. now owns 10,299 shares of the medical technology company’s stock valued at $127,000 after acquiring an additional 10,034 shares in the last quarter. Institutional investors and hedge funds own 74.67% of the company’s stock.

Shares of SYK traded up $2.14 during midday trading on Thursday, hitting $187.18. 53,185 shares of the company traded hands, compared to its average volume of 1,352,649. Stryker has a one year low of $144.75 and a one year high of $199.85. The stock has a market cap of $69.76 billion, a PE ratio of 25.60, a P/E/G ratio of 2.27 and a beta of 0.88. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.84 by $0.04. Stryker had a return on equity of 27.58% and a net margin of 25.38%. The firm had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the prior year, the business posted $1.68 earnings per share. The company’s revenue was up 8.5% on a year-over-year basis. Analysts expect that Stryker will post 8.13 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date is Thursday, March 28th. Stryker’s payout ratio is 28.45%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Why does a company issue an IPO?

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.